The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Poway, United States
11-50 Employees
2011
Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. Fulgent Genetics was the first clinical laboratory to offer copy number variation detection using NGS technology in the United States. Today, we continue to offer an unrivaled catalog of genetic testing, including over 18,000+ single gene tests, 900+ rare disease tests, whole genome sequencing, whole genome copy number variation analysis, mitochondrial sequencing, and CLIA/CAP quality sequencing services. We currently operate 7 labs across the United States, all of which are CLIA-certified and CAP-accredited and meet the highest standards of diagnostic testing.
+
Featured
Epilepsy - Fulgent Genetics - Leader in Next Generation Sequencing
... Epilepsy - Fulgent Genetics - Leader in Next Generation Sequencing ...
Cape Town, South Africa
251-500 Employees
2020
Our services are developed and validated using world class datasets and state-of-the-art technology to ensure the highest level of qual. Our services are developed and validated using world class datasets and state-of-the-art technology and approaches to ensure the highest level of quality. Our services combine cutting-edge, information-rich omics technologies with data sciences and bio-computational applications to convert digital big omics data into scientific knowledge alongside clinical and pharmaceutical applications. Of course, we are also pleased to help you with the interpretation and reporting of the results. We provide the clients our automate state-of-the-art app for an affordable personalized athletic performance prediction and track. We provide variants analysis including high-quality mapping of short and long read data, biological annotation, Protein-Protein Interaction analysis, in silico mutation prioritization and summarizing SNPs, InDels, and CNVs in your sample. Omics Data Solutions is an expert organization offering comprehensive solutions in all aspects of digital ‘omics’ data science to help transform omics data into knowledge. Biomedical data and “Omics” provide an awesome opportunity to improve understanding of the mechanisms of disease and ultimately to improve human health care.
+
Featured
Bioinformatics For Next Generation Sequencing Technologies
... Bioinformatics For Next Generation Sequencing Technologies – Omics Data ...
Lyon, France
1-10 Employees
2017
Each analysis may produce different files but here is a non-exhaustive list of popular items. As much as mass-production services are needed, it is understandably difficult for them to customize pipelines for each customer. Unfortunately, there never is a straight answer to this question. Whether you want more information about FITC or you would like to get a quote, please feel free to contact me!
+
Featured
FITC – Fourel IT Consulting
... Fourel IT Consulting is a company dedicated to provide high quality bio-informatics analysis for Next Generation Sequencing (NGS) data. ...
51-100 Employees
1995
Invivoscribe offers a full range of oncology testing products and services (B- and T-cell clonality, NGS gene panels, MRD assays, and comprehensive bioinformatics software), all developed under ISO 13485 design control and manufactured in our cGMP facility. We are following this study testing with our internationally standardized NPM1 MRD Assay, confident that this productive partnership will bring further advancements and benefits to AML patients worldwide. Looking ahead, we are focused on further expanding and aligning our services globally. We are actively transferring and validating our service offerings of NGS tests, gene panels, bioinformatics, multiparametric flow cytometry assays, and MRD applications through our network of fully accredited laboratories in San Diego, Japan, China, and Germany to support clinical and pharma partners worldwide. Our goal is to assist our clinical trial partners seeking to expand enrollment in their international clinical trials, while maintaining patient confidentiality. Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise. Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls. Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|.
+
Featured
Next-Generation Sequencing (RUO)
... Validation of a Next-Generation Sequencing ...
Belgium
1-10 Employees
2020
Seqcess is an online platform that provides you with unbiased information, data analysis, and result processing specific to your Next Generation Sequencing requirements. The platform provides you with the information and/or tools that you need to answer your questions. From sample to variant, we aggregate information, process and manipulate data, and provide you with tailored solutions specific to your questions.
+
Featured
Seqcess - Next generation sequencing (NGS) consulting
... Seqcess is a next generation sequencing consultation platform. ...
Planegg, Germany
11-50 Employees
2001
IMGM is your outsourcing partner for demanding projects with a focus on Metagenomics, Biomarker Discovery, Biodistribution and Pharmacogenetics. At IMGM, we combine state-of-the-art technologies with complex data analysis to deliver meaningful results in an easy-to-understand format. Since 2019 IMGM Laboratories is part of Medicover Integrated Clinical Services (MICS), a subdivision of Medicover Diagnostics. IMGM Laboratories is part of Medicover Integrated Clinical Services (former Synevo Central Labs), a specialized business unit within the Medicover Diagnostic Services division with the overarching objective to help bring innovative therapies and diagnostics to the market working with pharmaceuticals. Our goal is to serve the needs of international life science partners wishing to tap into the expertise, professionalism, enthusiasm, and work ethic in Germany and Central Eastern Europe, by providing the utmost quality at a reasonable cost, leveraging flexible and innovative thinking, disciplined management, and significant economies of scale with an attractive cost base. IMGM offers a wide range of services to support you in the discovery of biomarkers. At IMGM, our expert team has long-standing experience in complex assay design and validation, resulting in high-quality data. We offer complete solutions to our customers from pharma, diagnostics, biotech and academia according to your project requirements.
+
Featured
Next Generation Sequencing
... IMGM Laboratories GmbH - Next Generation Sequencing ...
Hercules, United States
11-50 Employees
2007
Eureka Genomics proprietary algorithms and genomic data collections can be applied to:.
+
Featured
Barley SNP Panel | NEXT GENERATION SEQUENCING | EUREKA GENOMICS
... Barley SNP Panel | NEXT GENERATION SEQUENCING | EUREKA ...
Singapore, Singapore
11-50 Employees
Macrogen APAC is a wholly owned subsidiary of Macrogen, Inc. Macrogen is one of the largest provider of genomics services in the world. Macrogen provides Sanger Sequencing services from its laboratory at Biopolis, with results available within 24 hours. Next Generation Sequencing is the method of reading a genome by dividing it into many pieces, assembling the obtained sequence pieces and analyzing the sequence of the whole genome. Capillary Electrophoresis Sequencing (CES) is a service that analyzes DNA sequences using a biochemical method. Macrogen provides genomics services for research use, as well as clinical diagnostics worldwide, with laboratories in 6 countries, and more than 18,000 customers in 153 countries. Exhibition booth showcases Macrogen services, including new CRISPR product launch.
+
Featured
Next Generation Sequencing (NGS)
... Next Generation Sequencing is the method of reading a genome by dividing it into many pieces, assembling the obtained sequence pieces and analyzing the sequence of the whole genome. ...
Silkeborg, Denmark
1-10 Employees
2021
At Data-Set-Go, we offer services within Bioinformatics, Programming, and Clinical Trial Management. Let us help you extract useful information from big data and provide reusable pipelines for future experiments. With over 10 years of experience in scientific research and publishing reproducible experiments, co-founder Maibritt Mardahl has a true passion for unraveling our understanding of molecular biology. Co-founder Ricki Gregersen, is a senior software engineer with over 15 years of experience in writing and documenting code. We combine the best of these communities to provide tailored bioinformatic pipelines. We document every step and deliver a detailed report containing publication-ready figures and a bioinformatic pipeline you can reuse in future experiments. Over 10 years of experience as a research scientist in the academic research community. Software engineer with 15 years of experience in solving computer science, data, and application challenges.
+
Featured
Data Analysis | Data Set Go
... analysis, next generation sequencing, data automation, biological and big data pipelines. data-set- ...
Berlin, Germany
11-50 Employees
2005
Wir sind ein Berliner Unternehmen, das sich auf die Entwicklung, Herstellung und den Vertrieb von diagnostischen Reagenzien und Systemlösungen für die Bereiche Immunhistologie, In-situ-Hybridisierung und Molekularpathologie spezialisiert hat. Unser Ziel ist es, unsere Produkte Ihrem Bedarf exakt anzupassen. Mit dem CE/IVD-klassifizierten VisionArray®-System unserer Schwesterfirma ZytoVision ist ein sensitiver, DNA-Chip-basierter Nachweis von Mykobakterien, humanen Papillomviren (HPV) und pilzlichen Erregern möglich. Wir bieten das DNA-Chip-System VisionArray® unserer Schwesterfirma ZytoVision für den HPV-Nachweis an. Die biotinylierten PCR-Produkte werden dann auf einem Array mit HPV-Fängersonden hybridisiert. Der VisionArray® MYCO Chip 2.0 unserer Schwesterfirma ZytoVision ist ein DNA-Array für den Nachweis von Mykobakterien. VisionArray® ist ein eingetragener Markenname der ZytoVision GmbH. Momentan verfügt unsere Produktionsstätte nicht über die Kapazität, Antikörper im Auftrag zu produzieren.
+
Featured
Next Generation Sequencing (NGS)
... Next Generation Sequencing (NGS) | Zytomed ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Next-Generation Sequencing
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 187 |
| Amount of suitable service providers | 177 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1995 |
| Youngest suiting company | 2021 |
Next-Generation Sequencing (NGS) represents a high-throughput methodology that allows for the rapid sequencing of the base pairs in DNA or RNA samples. This advanced technology has revolutionized the genomics field by enabling the sequencing of entire genomes swiftly and more cost-effectively than the traditional Sanger sequencing. NGS stands out by its ability to process multiple DNA strands simultaneously, significantly accelerating genetic analysis and reducing the time required to analyze large samples of genetic material. The impact of NGS within its field is profound, offering a broad range of applications from genomic research, personalized medicine, and disease diagnosis to agricultural biotechnology. By providing a deeper understanding of genetic variation and function, NGS technologies have paved the way for new discoveries in genetics and molecular biology. This has led to advancements in identifying genetic mutations associated with specific diseases, enabling the development of targeted therapies. Furthermore, NGS plays a critical role in precision medicine, where genetic information is used to tailor medical treatments to individual patients. The ability of NGS to generate vast amounts of genomic data quickly and accurately is instrumental in advancing research, improving disease diagnostics, and enhancing the overall understanding of complex genetic factors influencing health and disease.
1. Increased Throughput
Next-Generation Sequencing (NGS) offers the capability to process millions of DNA sequences simultaneously. This high-throughput approach significantly reduces the time required for genomic studies, enabling researchers to conduct large-scale projects efficiently.
2. Cost-Effectiveness
Despite the sophisticated technology involved, NGS has become more affordable over time. The cost per genome sequenced has dramatically decreased, making it accessible for a broader range of scientific research and clinical applications compared to traditional sequencing methods.
3. Enhanced Accuracy and Sensitivity
NGS technologies provide a higher resolution of genetic data, allowing for the detection of rare mutations and low-frequency variants with greater precision. This level of sensitivity is crucial for understanding complex genetic disorders, advancing personalized medicine, and identifying novel therapeutic targets.
4. Flexibility and Scalability
The adaptable nature of NGS platforms supports a wide array of genomic applications, from whole-genome sequencing to targeted gene panels. Researchers can tailor the scale of their experiments to specific project needs, making NGS a versatile tool for genomic exploration.
While evaluating the different suppliers make sure to check the following criteria:
1. Technology and Platform
Ensure the supplier employs the latest next-generation sequencing technologies and platforms, offering high-throughput capabilities and accuracy.
2. Data Quality and Read Length
Consider the quality of data (Q-scores) and the read lengths provided, as these factors significantly impact the depth of sequencing and the ability to detect variants.
3. Turnaround Time
Evaluate the supplier's ability to deliver results within a reasonable timeframe, understanding the impact of turnaround time on project timelines.
4. Cost Efficiency
Compare costs, including sequencing and any additional fees (e.g., library preparation, data analysis) to find the best value proposition.
5. Customer Support and Consultation
Assess the level of customer support provided, including pre-sequencing consultation and post-sequencing analysis assistance.
6. Scalability and Flexibility
Determine if the supplier can scale operations to meet your project's size and complexity, and if they offer flexible sequencing options to suit different needs.
7. Data Security and Confidentiality
Ensure the supplier has robust measures in place to protect your data's security and confidentiality throughout the sequencing process.
Next-generation sequencing (NGS) has revolutionized various industries by providing deep insights into genetic information, leading to enhanced decision-making. In healthcare and pharmaceuticals, NGS is instrumental in personalized medicine, enabling the development of treatments tailored to an individual's genetic makeup. This approach significantly improves the efficacy of therapies and reduces adverse drug reactions, optimizing patient care and outcomes. In agriculture, NGS aids in crop improvement and livestock management. By understanding the genetic traits of plants and animals, businesses can select for desirable qualities such as disease resistance, yield, and quality. This genetic insight accelerates breeding programs and enhances food security by supporting the development of more resilient and productive agricultural systems. The environmental sector benefits from NGS through biodiversity assessment and monitoring. Companies specializing in environmental consultancy use NGS to analyze microbial communities and ecosystems. This information is vital for assessing environmental health, managing natural resources sustainably, and aiding in the restoration of degraded ecosystems. Lastly, in the field of biotechnology, NGS fuels innovation in genetic engineering and synthetic biology. Companies leverage NGS data to engineer organisms with novel capabilities, opening new avenues for industrial bioprocessing, renewable energy production, and environmental remediation. This use case underscores the role of NGS in driving forward technological advancements and sustainable solutions across industries.
Next-Generation Sequencing (NGS) technologies have advanced significantly, reaching a high Technology Readiness Level (TRL) of 8 to 9. This classification indicates that NGS methods are fully developed, thoroughly tested, and validated in real-world settings. The progression to such a high TRL stems from extensive research and development efforts that have led to notable technical enhancements, including substantial improvements in sequencing speed, cost reduction, and data accuracy. Innovations such as high-throughput sequencing technologies have enabled the sequencing of entire genomes quickly and at a fraction of the cost compared to first-generation methods. Furthermore, the development of sophisticated bioinformatics tools has resolved many of the data analysis challenges previously associated with NGS, facilitating the extraction of meaningful insights from complex genetic data. The integration of NGS into clinical diagnostics, personalized medicine, and agricultural biotechnology underscores its maturity and reliability. These applications demonstrate the technology's capability to operate effectively under specific conditions, confirming its high TRL status. The technical reasons for this level of readiness include the successful demonstration of the technology's scalability, the robustness of data analysis algorithms, and the widespread adoption of NGS platforms across various scientific and medical fields.
In the Short-Term, advancements in Next-Generation Sequencing (NGS) technology are expected to focus on enhancing accuracy and reducing sequencing costs. Improvements in sequencing chemistry and the development of more efficient algorithms for data analysis will make NGS more accessible to smaller research institutions and clinics. This phase will also see the integration of NGS with other diagnostic tools, leading to more precise and personalized medical treatments. The Mid-Term outlook anticipates significant strides in throughput capabilities and the miniaturization of sequencing devices. These developments will enable portable NGS solutions, opening new avenues for real-time genetic analysis in the field and direct consumer applications. Further, the introduction of artificial intelligence and machine learning for data interpretation will streamline the diagnostic process, reducing the time from sample collection to actionable insights. Looking into the Long-Term, the horizon of NGS technology shows promise for achieving full genome sequencing at unprecedented speeds and costs, approaching the coveted goal of the $100 genome. This will be facilitated by breakthroughs in nanopore technology and the advent of quantum computing for data processing. The democratization of NGS will revolutionize personalized medicine, allowing for the routine inclusion of genetic screening in standard healthcare practices and significantly impacting preventive medicine and disease management.
